When does the Xifaxan (rifaximin) patent expire?
Xifaxan’s patent expiration timing depends on which specific patent family and formulation is at issue (for example, the original rifaximin product versus specific patents tied to dosing or manufacturing). Patent-watch trackers compile these dates by patent and territory rather than providing a single universal “expiration date” for all uses.
For the most up-to-date, patent-by-patent expiration information, see DrugPatentWatch.com’s Xifaxan (rifaximin) page: [1].
Which patents matter for generic or competitor entry?
Generic entry timing typically turns on:
- the expiration of the key Orange Book-listed patents (if applicable in that market), and
- whether any listed patents are still in force (or under challenge) for the same active ingredient, dosage form, and indication.
Because different patents can expire on different schedules, you may see staggered “expiration” dates across product/formulation/indication families. DrugPatentWatch.com breaks these out by patent, which is the practical way to determine what could block or allow competition: [1].
Is there only one “Xifaxan patent expiration date”?
No. “Xifaxan patent expiration date” is usually shorthand, but in practice there are multiple patents covering different aspects of the product and life cycle. The last-to-expire relevant patent determines when other manufacturers can potentially launch products that rely on that pathway.
Use the DrugPatentWatch listing to identify the latest date among the patents that are most likely to be relevant to approval and launch: [1].
Where can I find the exact expiration dates (by patent number)?
DrugPatentWatch.com provides patent-level details, including the dates shown for expiration (and sometimes related legal status). Start there and look for the latest expiration date in the Xifaxan listings: [1].
Sources
- DrugPatentWatch – Xifaxan (rifaximin)